Skip to Content
Upcoming Webinar

September 2025 International Monthly Webinar

Date: September 25, 2025 | 2:00 PM

Date: Thursday, September 25, 2025
Time: 2 p.m. Eastern

This month’s webinar brings together three important conversations at the intersection of policy and practice: preparing for Medicare Part D changes, using DPYD testing to make fluoropyrimidine treatment safer, and understanding a new therapy for steroid-refractory chronic GVHD.

  • Medicare D & Open Enrollment Joan Martens (American Oncology Network Pharmacy) will explain how the 2026 Medicare Part D updates will reshape coverage and costs, and what you can do now to guide patients during this year’s open enrollment period.
  • DPYD Testing in Fluoropyrimidine Treatment Daniel Hertz, PharmD, PhD (University of Michigan College of Pharmacy), will highlight how testing for DPYD variants can reduce serious toxicities, summarize where current guidelines stand, and share how to apply results to dosing decisions and patient counseling.
  • Axatilimab in Steroid-Refractory cGVHDBrooke Adams, PharmD, BCOP (Orlando Health Cancer Institute), will walk through the role of CSF-1R–dependent monocytes and macrophages in chronic GVHD, and review the trial data that supported axatilimab’s FDA approval as a new option for patients who do not respond to steroids.

We’ll begin with opening remarks from Megan May, PharmD, BCOP, FHOPA, FAPO (Baptist Health Lexington/Hamburg).

You’ll leave with a clearer understanding of:

  • How Medicare policy changes will impact patient conversations and practice workflows.
  • Why DPYD testing is becoming essential in fluoropyrimidine therapy and how to implement it in daily care.
  • How axatilimab works, and where it fits in for patients with steroid-refractory chronic GVHD.

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.